Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells $119,865.60 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Christine Ring sold 5,760 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $20.81, for a total transaction of $119,865.60. Following the sale, the insider now owns 19,838 shares in the company, valued at $412,828.78. The sale was disclosed in a filing with the SEC, which is available at this link.

Christine Ring also recently made the following trade(s):

• On Wednesday, June 12th, Christine Ring sold 1,900 shares of Nurix Therapeutics stock. The shares were sold at an average price of $17.01, for a total transaction of $32,319.00.
• On Wednesday, June 5th, Christine Ring sold 400 shares of Nurix Therapeutics stock. The shares were sold at an average price of $17.00, for a total transaction of $6,800.00.
• On Monday, June 3rd, Christine Ring sold 1,596 shares of Nurix Therapeutics stock. The shares were sold at an average price of $17.01, for a total transaction of $27,147.96.

Nurix Therapeutics Stock Performance

Shares of NRIX stock opened at $19.41 on Thursday. The company’s 50-day simple moving average is $16.15 and its two-hundred day simple moving average is $13.09. Nurix Therapeutics, Inc. has a one year low of $4.22 and a one year high of $22.44.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Wednesday, April 10th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.04. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. The firm had revenue of $16.59 million during the quarter, compared to analysts’ expectations of $14.58 million. On average, analysts anticipate that Nurix Therapeutics, Inc. will post -2.85 EPS for the current fiscal year.

Institutional Investors Weigh In On Nurix Therapeutics

Several hedge funds have recently modified their holdings of the business. ProShare Advisors LLC lifted its position in shares of Nurix Therapeutics by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock worth $176,000 after purchasing an additional 998 shares during the period. Public Employees Retirement System of Ohio lifted its position in shares of Nurix Therapeutics by 3.7% in the 1st quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock worth $747,000 after purchasing an additional 1,820 shares during the period. Raymond James & Associates lifted its position in shares of Nurix Therapeutics by 3.1% in the 4th quarter. Raymond James & Associates now owns 101,006 shares of the company’s stock worth $1,042,000 after purchasing an additional 3,018 shares during the period. GAMMA Investing LLC lifted its position in shares of Nurix Therapeutics by 299.8% in the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after purchasing an additional 3,424 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Nurix Therapeutics by 67.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock worth $138,000 after purchasing an additional 3,793 shares during the period.

Analyst Ratings Changes

Several equities analysts recently commented on NRIX shares. Needham & Company LLC reiterated a “buy” rating and set a $31.00 price target on shares of Nurix Therapeutics in a report on Monday, June 17th. Stephens started coverage on shares of Nurix Therapeutics in a report on Tuesday, May 14th. They set an “overweight” rating and a $20.00 price target on the stock. Royal Bank of Canada upped their price target on shares of Nurix Therapeutics from $23.00 to $26.00 and gave the company an “outperform” rating in a report on Thursday, June 27th. Stifel Nicolaus reiterated a “buy” rating and set a $27.00 price target on shares of Nurix Therapeutics in a report on Wednesday, May 15th. Finally, HC Wainwright upped their price target on shares of Nurix Therapeutics from $19.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, June 18th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $25.10.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.